Strategic Workshops Supporting Pharma’s Future
Richard Withers, Strategic Advisor
How to deliver the degree of holistic and objective understanding that today’s market demands
For any company seeking success, strategic intelligence is crucial.
For the pharma industry, the questions surrounding how to win have become increasingly complex, and the answers even more so. Distilling and prioritising the information crucial to strategy-formation can appear a labrynthine task.
So how do you deliver the degree of holistic – and objective – understanding that today’s circuitous market demands? Should you challenge your existing business model? And how can you prepare for the next disruption?
Breakthrough thinking, we’ve seen, lies in the prioritization of a full Strategic Preparedness Workshop (SPW). The SPW goes far beyond traditional pharma workshops that assess one or a few competitors or helps to clarify the path to an already clear-cut goal. Instead, SPWs align key stakeholders early in the direction setting process via a thorough exploration of the strategic challenges, disruptors, and opportunities facing a company. SPWs give leaders a chance to align, engage, and explore the best strategic approach based on deep knowledge of external as well as internal success factors.
In this paper, we’ll show how SPWs should be run – and why.
Richard founded Deallus in 2004 and brings a strong military intelligence background to the life sciences consulting world. He was essential in forming Deallus’ original vision and understanding the value that CI could bring to pharmaceutical clients. As a strategic advisor he works closely with the leadership team to ensure that we continue to deliver best-in class competitive and strategic intelligence to our clients. Richard is adept at supporting the facilitation of workshops, competitive simulations and direction-setting sessions for our clients.
As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.
COVID-19 is throwing a wrench in years’ worth of launch planning, introducing complications and delays into the regulatory process and severely constricting promotional and educational opportunities for new products. How is the pharmaceutical industry responding to these changes in well-laid plans? How are regulatory bodies responding? We consider the potential impact of the pandemic on launch timing and strategy here.
As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.
Deallus is excited to announce that Jenny Cummins will be partnering with Deallus as a Strategic Advisor. Jenny’s experience in formulating strategic direction within and outside of pharmaceutical companies is something we are excited to add to our panel of strategic advisors. Our clients will benefit from her expertise in the healthcare sector as well as her impressive leadership, communication, and facilitation skills.